International Normalized Ratio Calculator

Prothrombin time (PT) measures how long plasma takes to clot after adding calcium and a thromboplastin reagent that activates the extrinsic and common coagulation pathways — the pathway warfarin suppresses by blocking vitamin K-dependent synthesis of clotting factors II, VII, IX, and X. The raw PT in seconds is not portable between labs because different manufacturers' thromboplastin reagents have different sensitivities to factor depletion; the same patient's blood could report a very different PT depending on which reagent brand the lab uses. The INR normalizes this by raising the PT ratio (patient PT divided by the lab's mean normal PT) to the power of the reagent's International Sensitivity Index (ISI), a calibration factor supplied by the reagent manufacturer against a WHO international reference thromboplastin. An ISI near 1.0 means the reagent behaves like the reference standard and the correction is minimal; a less sensitive reagent has a higher ISI and requires a larger correction. Target INR ranges are indication-specific: 2.0-3.0 for atrial fibrillation and most venous thromboembolism, and a higher 2.5-3.5 for mechanical mitral valves and some mechanical aortic valves, reflecting their substantially greater thrombogenic risk if underanticoagulated.

Armand Quick developed the original one-stage prothrombin time test in 1935, giving clinicians the first practical laboratory measure of the extrinsic coagulation pathway and, soon after, a way to monitor the newly emerging class of oral anticoagulants derived from dicoumarol research at the University of Wisconsin in the 1940s. For decades, PT results were reported as a simple ratio to a local laboratory's own normal control, with no standardization between institutions or reagent manufacturers. By the late 1970s it was clear that this lack of standardization was causing dangerously inconsistent anticoagulation dosing between hospitals, since identical blood samples produced meaningfully different PT ratios depending on which thromboplastin reagent a lab used. The World Health Organization's Expert Committee on Biological Standardization introduced the International Normalized Ratio system in 1982-83, formally defining the ISI calibration against WHO international reference thromboplastin preparations. INR reporting became the global standard through the 1980s and 1990s and was subsequently codified into American Heart Association/American College of Cardiology Foundation warfarin monitoring guidance, remaining the universal metric for vitamin K antagonist anticoagulation monitoring even as direct oral anticoagulants have reduced reliance on warfarin for many indications.